ADVM Projected Dividend Yield
Adverum Biotechnologies Inc ( NASDAQ : ADVM )Adverum Biotechnologies is a clinical-stage company focused on establishing gene therapy as a standard of care for ocular diseases. Co.'s main product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection. 20 YEAR PERFORMANCE RESULTS |
ADVM Dividend History Detail ADVM Dividend News ADVM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |